Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report

The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course ha...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis and related disorders 2020-09, Vol.44, p.102323-102323, Article 102323
Main Authors: Lucchini, Matteo, Bianco, Assunta, Del Giacomo, Paola, De Fino, Chiara, Nociti, Viviana, Mirabella, Massimiliano
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - therapeutic use
Correspondence
COVID-19
COVID-19 - complications
COVID-19 - diagnosis
COVID-19 - immunology
COVID-19 Serological Testing
Female
Humans
IgA
IgG
Immunoglobulin A - analysis
Immunoglobulin A - immunology
Immunoglobulin G - analysis
Immunoglobulin G - immunology
Immunologic Factors - therapeutic use
Middle Aged
Multiple Sclerosis - complications
Multiple Sclerosis - drug therapy
Multiple Sclerosis - immunology
Ocrelizumab
Serology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course have recently been published. We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. Patients on B-cell depleting drugs have a reduced antibody immune response to viral neoantigens. A relative sparing of mucosal-associated lymphoid tissues (MALT) could be responsible for IgA response in our patient.
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2020.102323